For Industry

Public Meeting on Idiopathic Pulmonary Fibrosis Patient-Focused Drug Development

On September 26, 2014, FDA is conducting a public meeting on Patient-Focused Drug Development for idiopathic pulmonary fibrosis (IPF). FDA is interested in obtaining patient input on the impact of IPF on daily life and patients’ views on currently available therapies to treat the condition.

This website will be updated as meeting materials are developed.

Date:September 26, 2014
Time:1:00 p.m. to 5:00 p.m.
Location:FDA White Oak Campus
10903 New Hampshire Ave.
Building 31, Room 1503B and C (Great Room)
Silver Spring, MD 20993
Parking is available in lot 132B
(Information about arrival to FDA's White Oak campus)

Registration
To register for this meeting, visit: Public Meeting on Idiopathic Pulmonary Fibrosis Patient-Focused Drug Development
Registration closed on September 17, 2014
 

Submitting comments to the docket: In addition to providing input at the public meeting, patient stakeholders are invited to provide their perspectives on the discussion questions through the public docket. The docket closes on November 26, 2014.

Webcast Recordings